Table 3.
The effect of GATA3 genotypes on the treatment response and outcome in pediatric ALL.
| CC (N = 109) | CA (N = 116) | AA (N = 31) | P-value | |
|---|---|---|---|---|
| Prednisone Response, n (%) | 0.011* | |||
| Good | 97 (89.0) | 105 (90.5) | 22 (71.0) | |
| Poor | 12 (11.0) | 11 (9.5) | 9 (29.0) | |
| Day 15th BM, n (%) | 0.007* | |||
| M1 + M2 | 89(81.7) | 100 (86.2) | 19 (61.3) | |
| M3 | 20 (18.4) | 16 (13.8) | 12 (38.7) | |
| Day 33rd MRD, n (%) | 0.606 | |||
| <1 × 10−3 | 80(80.0) | 84 (80.8) | 21 (72.4) | |
| ≥1 × 10−3 | 20 (20.0) | 20 (19.2) | 8 (27.6) | |
| Week 12th MRD, n (%) | 0.521 | |||
| <1 × 10−4 | 67(69.8) | 65 (68.4) | 17 (58.6) | |
| ≥1 × 10−4 | 29 (30.2) | 30 (31.6) | 12 (41.4) | |
| Risk group, n (%) | 0.027* | |||
| Standard risk | 23(21.1) | 38 (32.8) | 5 (16.1) | |
| Intermediate risk | 50 (45.9) | 45 (38.8) | 10 (32.3) | |
| High risk | 36 (33.0) | 33 (28.5) | 16 (51.6) | |
| Relapse, n (%) | 0.355 | |||
| Yes | 31(28.4) | 38 (32.8) | 13 (41.9) | |
| No | 78 (71.6) | 78 (67.2) | 18 (50.1) | |
| Relapse stage, n (%) | 0.409 | |||
| Very early stage | 8(25.8) | 16 (42.1) | 5 (38.5) | |
| Early stage | 9 (29.0) | 8 (21.5) | 1 (7.7) | |
| Late stage | 14 (45.2) | 14 (36.8) | 7 (53.8) | |
| Survival times, SE | ||||
| 10-years OS, cumulative survival | 85.2 (3.4) | 84.1 (3.4) | 77.4 (7.5) | 0.616 |
| 10-years EFS, cumulative survival | 68.8 (4.4) | 66.8 (4.4) | 57.9 (8.9) | 0.618 |
| 10-years RFS, cumulative survival | 70.1 (4.4) | 66.6 (4.4) | 57.9 (8.9) | 0.502 |
| Adverse events, n (%) | ||||
| Sepsis | 0.021* | |||
| Yes | 48 (44.0) | 52 (44.8) | 22 (70.9) | |
| No | 61 (56.0) | 64 (55.2) | 9 (29.1) | |
| Pneumonia | 0.208 | |||
| Yes | 30 (27.5) | 44 (37.9) | 12 (38.7) | |
| No | 79 (72.5) | 72 (62.1) | 19 (61.3) | |
| Myelosuppression | 0.254 | |||
| Yes | 84 (77.1) | 94 (81.0) | 28 (90.3) | |
| No | 25 (22.9) | 22 (19.0) | 3 (9.7) | |
| Liver dysfunction | 0.536 | |||
| Yes | 19 (17.5) | 25 (21.5) | 8 (25.8) | |
| No | 90 (82.5) | 91 (78.5) | 23 (74.2) |
BM, bone marrow; MRD, minimal residual disease detected by Flow cytometry; SE, standard error.
*
Significant P-value.